Efitaz

IV Infusion

Radiant Pharmaceuticals Ltd.

Generic:

Piperacillin + Tazobactam

Weight:

(4 gm+0.5 gm)/vial

best Price:

? 1,003.00

Single

? 1,003.00

Description Upload Prescription

Generic

Piperacillin + Tazobactam

Indications

Piperacillin and tazobactam is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a ?-lactamase inhibitor, tazobactam, indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of the designated bacteria in the ... Read morePiperacillin and tazobactam is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a ?-lactamase inhibitor, tazobactam, indicated for the treatment of patients with moderate to severe infections caused by susceptible isolates of the designated bacteria in the conditions listed below. Intra-abdominal Infections: Appendicitis (complicated by rupture or abscess) and peritonitis caused by ?-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis, B. ovatus, B. thetaiotaomicron, or B. vulgatus. Skin and Skin Structure Infections: Uncomplicated and complicated skin and skin structure infections, including Cellulites, cutaneous abscesses and ischemic/diabetic foot infections caused by ?-lactamase producing isolates of Staphylococcus aureus. Female Pelvic Infections: Postpartum endometritis or pelvic inflammatory disease caused by ?-lactamase producing isolates of Escherichia coli. Community-acquired pneumonia: Community-acquired pneumonia (moderate severity only) caused by ? lactamase producing isolates of Haemophilus influenzae. Nosocomial pneumonia: Nosocomial pneumonia (moderate to severe) caused by ?-lactamase producing isolates of Staphylococcus aureus and by piperacillin/tazobactam-susceptible Acinetobacter baumanii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside).

Pharmacology

Piperacillin, a broad spectrum, semi-synthetic penicillin active against many gram-positive and gram-negative aerobic and anaerobic bacteria, exerts bactericidal activity by inhibition of both septum and cell wall synthesis. Tazobactam is a potent inhibitor of many beta-lactamases, including the plasmid and chromosomally mediated enzymes that commonly cause resistance to penicillins. Tazobactam enhances and extends the antibiotic spectrum of Piperacillin to include many beta-lactamase-producing bacteria normally resistant to it. Thus, this infusion combines the properties of a broad-spectrum antibiotic and a beta-lactamase inhibitor.

Dosage Administration

Piperacillin and tazobactam should be administered by intravenous infusion over 30 minutes. Adult Patients: The usual total daily dose of Piperacillin and tazobactam for adults is 3.375 g every six hours totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam). The usual duration of treatment is from 7 to 10 days. Nosocomial Pneumonia: Initial presumptive treatment of patients with nosocomial pneumonia should start with piperacillin and tazobactam at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18.0 g (16.0 g piperacillin/2.0 g tazobactam). The recommended duration of the treatment for nosocomial pneumonia is 7 to 14 days. Treatment with the aminoglycoside should be continued in patients from whom Pseudomonas aeroginosa is isolated. Pediatric Patients: For children with appendicitis and/or peritonitis 9 months of age or older, weighing up to 40 kg, and with normal renal function, the recommended piperacillin and tazobactam dosage is 100 mg piperacillin/12.5 mg tazobactam per kilogram of body weight, every 8 hours. For pediatric patients between 2 months and 9 months of age, the recommended dosage based on Pharmacokinetic modeling, is 80 mg piperacillin/10 mg tazobactam per kilogram of body weight, every 8 hours. Pediatric patients weighing over 40 kg and with normal renal function should receive the adult dose. It has not been determined how to adjust piperacillin and tazobactam dosage in pediatric patients with renal impairment.

Contraindications

Piperacillin and tazobactam is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or ? -lactamase inhibitors.

Side Effects

Adverse events primarily involving the skin, including rash, pruritus and Purpura; the gastrointestinal system including diarrhea, Constipation, nausea, vomiting, Dyspepsia and Abdominal Pain; General disorders and administration site conditions including Fever, Injection site reaction (?1%) and Rigors. (?1%), Immune hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock) (?1%), Infections-Candidiasis and Pseudomembranous colitis (?1%), Metabolism and nutrition disorders- Hypoglycemia (?1%), Musculoskeletal and connective tissue disorders- Myalgia and Arthralgia (?1%), Psychiatric disorders Insomnia, Vascular disorders- Phlebitis Thrombophlebitis(?1%), Hypotension(?1%), Flushing(?1%), Respiratory, thoracic and mediastinal disorders- Epistaxis (?1%).

Pregnancy And Lactation

Piperacillin and tazobactam cross the placenta in humans. However, there are insufficient data with piperacillin and/or tazobactam in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Piperacillin is excreted in human milk; tazobactam concentrations in human milk have not been studied. No information is available on the effects of piperacillin and tazobactam on the breastfed child or on milk production.

Therapeutic

Broad spectrum penicillins, Other beta-lactam Antibiotics

Storage Conditions